TB-500: Access Changed. What Did the Evidence Show?
Separate TB-500 compounding policy from drug approval, related molecules from one another, and laboratory findings from patient outcomes.
Opening dispatch · Fiction
EPISTIDE, FICTIONAL NARRATOR: “The access notice arrived. Someone rang the approval bell. Doctide asked to see the clinical trials.”
Which decision? Access changed; approval did not
TB-500 is a short, acetylated fragment related to thymosin beta-4. Its identity matters when interpreting research. The October HHS policy changes the enforcement approach to specified compounding; it does not establish that TB-500 heals injuries in people.
The October 30 notice describes a draft, interim, nonbinding policy while rulemaking proceeds. The accompanying document includes TB-500 among six listed substances, with ingredient identity, quality, prescription and reporting conditions. These conditions include a single active ingredient; this policy does not extend to a combined BPC-157/TB-500 product. Federal Register, October 30 · HHS policy and appendices.
Kennedy’s stated rationale is to move demand toward a more controlled alternative to unregulated supply. That rationale should be assessed separately from the clinical question: what benefits and harms have been demonstrated? July’s advisory discussion is historical background, not the latest policy event.
Which molecule?
DOCTIDE, FICTIONAL COMMENTARY: “A family resemblance is not a shared clinical record.”
FDA’s July 2026 scientific review distinguishes full-length thymosin beta-4, non-acetylated LKKTETQ and acetylated TB-500. Findings from the related molecules cannot automatically be transferred to TB-500. The briefing reported no identified in-vivo wound-healing pharmacology study for TB-500 itself and no identified nonclinical toxicity studies. These are the findings of that dated review. FDA July 2026 TB-500 briefing.
Which model?
A 2024 paper studied TB-500 metabolism in laboratory systems and rats. A separate fibroblast scratch assay examined wound closure in cultured cells. The metabolite Ac-LKKTE showed activity; parent TB-500 did not show the same signal. Rahaman and colleagues, 2024 research record.
Rats: metabolism. Cells: wound-closure assay. The rat work is not an animal injury-recovery result, and the cell assay is not evidence of faster recovery in a patient.
What remains unknown?
FDA’s briefing identifies safety uncertainties, including potential immunogenicity associated with peptide aggregation and impurities. An access policy does not fill missing human safety information or provide reliable adverse-event rates. No invented percentage risk or list of established common side effects is justified here.
PROFITIDE, FICTIONAL COMMENTARY: “Studied, available and approved fit neatly in the same sales pitch. They still mean different things.”
Subject One is a fictional observer, not a clinical result. His questions are the reader’s: Which molecule? Which model? Which decision?
Read the record
This companion uses the published research record, FDA’s dated scientific review and HHS’s later policy document for different questions. No seller’s efficacy claim or patient anecdote is used as proof. Independent clinical review: none completed.
Read the November 6 Gospel: The Ledger and the Laboratory
Satire in the story. Evidence in the record. Educational content; no dosing, sourcing or treatment instruction.